Disse helseteknologiene for deteksjon av tre toaletter vil bli klinisk testet i USA, Israel og Japan

Israeli digital health startup OutSense has been awarded a number of patents for key innovations in IoT technology, according to foreign media reports on 23 June. The technology gains life-saving medical insights by analysing human excrement. Selskapet har innlevert en serie på tre patenter som dekker deler av den medisinske toalettsensoren.

Three Toilets Detection Health Technologies

The first OutSense toilets detection health technologies is for the detection of blood hidden in the toilet bowl. This OutSense device uses reflected light from the toilet to determine the optical signature of hidden blood in faeces. Patents for this technology have been granted in the US, Europa, Japan og Kina.

A second toilets detection health technologies has been granted in Europe and applications for this patent are pending in other countries. It allows effective analysis of the many components of faeces and the spatial distribution of blood traces. On the basis of this analysis, OutSenses teknologi kan identifisere kilden til blod langs mage-tarmkanalen.

A third patent is pending for a technology that detects the dehydrated composition of urine through the analysis of urine and faeces.

Ifølge OutSense-sjef Yfat Scialom, who predicts that “med eksplosjonen av digital medisin, this kind of monitoring will become the norm”, OutSense says that the technology already approved and pending approval will provide broad protection for a person’s health by non-invasively extracting faeces and hidden blood from the urine. Hidden blood is essential for detecting colorectal cancer, inflammatorisk tarmsykdom og urinveisinfeksjoner.

Its solution consists of a multispectral optical sensor, en lyskilde og en autonom skjermingsenhet som inkluderer en WiFi-tilkobling. The device scans human excrement, identifies the optical footprint of faecal and urine components, sends the data to an AI-based cloud analysis and then provides indications of various diseases with great precision.

OutSense has developed tools to diagnose abnormalities in human excreta. Informasjon hentet fra blodprøver, kombinert med tilleggsanalyse av tiden fra blødning til utskillelse, gir detaljer om blødningspatologien. Its specific patterns can determine whether the bleeding is from a fissure or haemorrhoid, from a polyp, a tumour or from an ulcer.

At the beginning of June, OutSense kunngjorde at CommuniCare, et stort helseselskap med mer enn 90 healthcare facilities in the US, vil begynne å pilotere teknologien i år. I tillegg til denne piloten, OutSense also plans to conduct clinical trials in Israel and Japan.